Search
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIt was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. … The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound [A32046].
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113]
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigational[A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.
Dihydroergocristine
go.drugbank.com/drugs/DB13345Approved[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Lomitapide
go.drugbank.com/drugs/DB08827Approved[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … A7367] It was developed to address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized by
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalby Alkermes Inc. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Eslicarbazepine
go.drugbank.com/drugs/DB14575ApprovedEslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.